Fosun Pharmaceutical Gets NMPA Green Light for Phase I Study of Fibrosis Drug HLX6018
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
HKG: 2196
Shanghai Fosun Pharma Gets NMPA Green Light for Universal NK Cell Therapy GCK-01 Clinical Study
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
Shanghai Fosun Pharma Gets NMPA Green Light for XS-02 Solid Tumor Clinical Study
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
Shanghai Fosun Pharma’s GCK-01 CAR-NK Cell Therapy Gets Tacit Clinical Approval from China’s CDE
The China Center for Drug Evaluation (CDE) website has indicated that Shanghai Fosun Pharmaceutical (Group)...
Fosun Pharmaceutical Secures NMPA Approval for Phase II Study of FCN-338 and FCN-647 in Chronic Lymphocytic Leukemia
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has...
Fosun Pharmaceutical’s HanDaYuan Seeks NMPA Approval for Expanded Indications in Autoimmune Treatments
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...
Shanghai Fosun Pharmaceutical Partners with Nanning City to Broaden Collaboration in Biopharma and Beyond
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196，HKG: 2196), a Chinese pharmaceutical heavyweight, has entered...
Shanghai Fosun Pharmaceutical Receives NMPA Approval for Phase II Study of FCN-338 for Light Chain Amyloidosis
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
Shanghai Henlius Secures Indonesian Approval for HanSiZhuang in Small-Cell Lung Cancer
Shanghai Henlius Biotech Inc. (HKG: 2696) has received market approval from the Indonesian Food and...
Fosun’s HLX42 Receives Fast-Track Designation from FDA for NSCLC Treatment
Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196; SHA: 600196) has announced that its antibody-drug conjugate...
Fosun Pharmaceutical Secures GHIT Fund Investment for Malaria Drug Trial
Shanghai Fosun Pharmaceutical Co., Ltd (SHA: 600196, HKG: 2196) has received financial backing of JPY...
Shanghai Henlius Biotech Submits Another Application for Serplulimab in China
Shanghai Henlius Biotech Inc., (HKG: 2696) has announced a new market filing for its anti-programmed...
Fosun Pharma to Establish Greater Bay Area HQ in Shenzhen’s Pingshan District
Local media outlets report that Fosun International’s chairman, Guo Guangchang, announced at a business event...
Fosun Pharmaceutical Gets FDA Green Light for HLX42 ADC Clinical Study
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has received approval from the US...
Fosun Pharmaceutical’s FCN-437c filing Accepted for Review by China’s NMPA
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has announced that the National...
Fosun Pharmaceutical’s US Subsidiary Partners with Treehill Partners for Clinical-Stage Investments
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) through its US subsidiary, Fosun Pharma...
Shanghai Henlius Receives GMP Certification from ANVISA for Biosimilar Manufacturing
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary Shanghai Henlius Biotech,...
Shanghai Henlius Completes Phase I/II Study for Anti-VEGF mAb HLX04-O in Wet AMD
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary, Shanghai Henlius Biotech, Inc....
Amoytop Biotech’s Pegfilgrastim (Y Shape) Approved for Marketing by NMPA
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has received marketing approval from the National Medical...
Fosun Pharmaceutical’s Sisram Opens Wellness Center in Chicago for Beauty and Health
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the establishment of...